相关实验视频

Updated: May 5, 2026

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

在CTLA-4缺陷障碍中,阿巴塔cept可恢复失调的转录组和蛋白组特征

Mehmet Cihangir Catak¹, Naz Surucu², Feyza Bayram Catak¹

¹Department of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.

The Journal of allergy and clinical immunology

|September 18, 2025

概括

阿巴塞普治疗通过恢复T和B细胞群并逆转炎症途径来纠正LRBA缺乏和CTLA-4缺乏的免疫调节障碍. 这种治疗支持针对这些罕见的免疫疾病的个性化策略.

科学领域:

免疫学免疫学免疫学
遗传学遗传学是一个
系统生物学系统生物学

背景情况:

响应脂多糖的色类似 (LRBA) 缺乏和细胞毒性T淋巴细胞相关蛋白4 (CTLA-4) 缺乏是罕见的原发性免疫失调障碍.
这两种情况都会损害CTLA-4的维持,CTLA-4是一种关键的抑制检查点分子.
治疗阿巴塔塞普特 (CTLA-4-Ig融合蛋白) 的确切免疫效应尚不清楚.

研究的目的:

综合调查阿巴塞普特治疗对LRBA缺乏症和CTLA-4缺乏症患者的影响.
利用综合性多组学方法来了解阿巴切的免疫影响.

主要方法:

用纵向流细胞计量来评估免疫细胞种群.
针对性和单细胞转录组学被用来分析基因表达特征.
血蛋白质组学为蛋白质水平变化提供了洞察力.

主要成果:

阿巴切增加了胸膜输出,扩大了天真的T细胞和B细胞,同时减少了记忆T细胞和CD21低B细胞.
多组学分析显示CD28和T细胞受体信号的增加,以及抑制检查点的补偿上调 (LAG3,TIGIT,ADORA2A,VSIR,HAVCR2).
阿巴塞普治疗逆转了大多数转录和蛋白质异常,淋巴细胞的正常化比骨髓细胞更大,并区分了特定疾病的分子特征.

结论:

阿巴切有效地纠正了LRBA缺乏和CTLA-4缺乏的关键免疫电路.
综合性系统层面的方法确定了新的机制和治疗目标.
研究结果支持针对这些罕见的免疫疾病进行个性化干预策略.

关键词:

在CTLA-4缺陷中.在LRBA缺乏症下,这就是 abataceptcept.免疫检查点调节障碍免疫检查点调节障碍多种经济学概况分析

更多相关视频

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...